+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimilars of Factor X agonists Market by Product Type, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030- Product Image
Biosimilars of Factor X agonists Market by Product Type, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Biosimilars of Factor X agonists Market by Product Type, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6079267
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The biosimilar Factor X agonist market is advancing rapidly as scientific and regulatory innovation unlocks broader patient access and transformative value for healthcare systems globally. This dynamic sector enables payers and providers to address clinical and cost efficiencies while ensuring adherence to safety and efficacy standards essential for complex coagulation therapies.

Market Snapshot: Factor X Agonist Biosimilars

The biosimilars market for Factor X agonists has transitioned from early-stage development to a sophisticated frontier propelled by advanced biomanufacturing, streamlined regulatory pathways, and surging payer interest. As healthcare budgets tighten and demand for innovative, affordable treatments rises, these biosimilars are increasingly preferred to meet the dual imperatives of patient access and sustainable delivery. Key industry players are intensifying investments in manufacturing excellence and regulatory risk management to expedite market entry and reinforce competitive positioning.

Scope & Segmentation of the Factor X Agonist Biosimilars Market

This report presents an in-depth analysis of the Factor X agonist biosimilars sector, structuring insights across multiple dimensions for strategic clarity:

  • Product Types: Plasma-Derived Factor X, Recombinant Factor X
  • Indications:
    • Acquired Hemorrhagic Conditions (Liver Disease Related, Vitamin K Antagonist-Induced)
    • Congenital Deficiency (Moderate Deficiency, Severe Deficiency)
    • Hemorrhagic Prophylaxis (Long-Term, Perioperative)
  • Dosage Forms: Powder for Injection, Ready-To-Use Injection
  • Distribution Channels: Hospital Pharmacy (Inpatient, Outpatient), Online Pharmacy (Prescription Service, Subscription Service), Retail Pharmacy (Chain, Independent)
  • End Users: Home Healthcare (Nurse Administration, Self-Administration), Hospitals (Community, Tertiary Care Centers), Specialty Clinics (Cardiology, Hemophilia Centers)
  • Regions: Americas (including US, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (UK, Germany, France, and other nations), Asia-Pacific (China, India, Japan, Australia, among others)
  • Key Companies Profiled: Sandoz International GmbH, Celltrion, Pfizer, Samsung Bioepis, Biocon Limited, Amgen, Fresenius Kabi, Boehringer Ingelheim, Viatris, Dr. Reddy’s Laboratories

Key Takeaways for Decision-Makers

  • Technological advancements in cell line development and continuous bioprocessing are accelerating production timelines and driving higher batch consistency.
  • Regulators in leading markets are cultivating predictable, expedited approval environments, encouraging investment in biosimilar pipeline development.
  • Payer and provider adoption is being shaped by value-based agreements, with a shift toward therapeutic outcomes and real-world patient evidence as negotiation levers.
  • Digital health platforms enhance biosimilar adoption by enabling remote monitoring, streamlined patient support, and improved adherence tracking.
  • Strategic segment differentiation – from recombinant products for advanced hospital settings to ready-to-use formulations for outpatient and home use – guides market entry prioritization and portfolio development.
  • Regional nuances, particularly in Asia-Pacific and EMEA, influence procurement strategies, reimbursement models, and the tempo of biosimilar uptake.

Tariff Impact and Strategic Response: United States 2025 Outlook

The 2025 US tariff measures on biosimilar Factor X agonists have introduced significant cost pressures on imported raw materials and finished products. Companies are mitigating these effects by reshaping supply chains, increasing local production, and forging domestic alliances with contract manufacturers. Early risk assessment and adaptive procurement models are proving vital in neutralizing margin erosion, ensuring consistent product availability, and sustaining profitability. These tariff-driven changes also reinforce industry-wide focus on reshoring and regional supply resilience.

Methodology & Data Sources

Insights are derived from comprehensive primary interviews with executives in biomanufacturing, regulatory, and commercial roles, alongside secondary research of regulatory filings, scientific journal publications, and market intelligence sources. Rigorous peer review and method audits underpin the reliability of every finding.

Why This Report Matters

  • Equips senior leaders with actionable intelligence for navigating complex regulatory, supply chain, and reimbursement environments in biosimilar Factor X agonists.
  • Provides clear segmentation analysis, enabling tailored go-to-market and investment strategies that target specific geographies and user needs.
  • Facilitates informed scenario planning by synthesizing technology trends, competitive strategies, and evolving tariff frameworks.

Conclusion

The Factor X agonist biosimilars market stands at a pivotal inflection point, driven by coordinated technological, regulatory, and commercial innovation. Organizations that leverage early regulatory engagement, robust risk mitigation, and strategic segmentation are poised for sustained growth and broader healthcare impact.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biosimilars of Factor X agonists Market, by Product Type
8.1. Introduction
8.2. Plasma-Derived Factor X
8.3. Recombinant Factor X
9. Biosimilars of Factor X agonists Market, by Indication
9.1. Introduction
9.2. Acquired Hemorrhagic Conditions
9.2.1. Liver Disease Related
9.2.2. Vitamin K Antagonist-Induced
9.3. Congenital Deficiency
9.3.1. Moderate Deficiency
9.3.2. Severe Deficiency
9.4. Hemorrhagic Prophylaxis
9.4.1. Long-Term Prophylaxis
9.4.2. Perioperative Prophylaxis
10. Biosimilars of Factor X agonists Market, by Dosage Form
10.1. Introduction
10.2. Powder For Injection
10.3. Ready-To-Use Injection
11. Biosimilars of Factor X agonists Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.2.1. Inpatient Pharmacy
11.2.2. Outpatient Pharmacy
11.3. Online Pharmacy
11.3.1. Prescription Service
11.3.2. Subscription Service
11.4. Retail Pharmacy
11.4.1. Chain Pharmacy
11.4.2. Independent Pharmacy
12. Biosimilars of Factor X agonists Market, by End User
12.1. Introduction
12.2. Home Healthcare
12.2.1. Nurse Administration
12.2.2. Self-Administration
12.3. Hospitals
12.3.1. Community Hospital
12.3.2. Tertiary Care Center
12.4. Specialty Clinics
12.4.1. Cardiology Clinic
12.4.2. Hemophilia Treatment Center
13. Americas Biosimilars of Factor X agonists Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Biosimilars of Factor X agonists Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Biosimilars of Factor X agonists Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Sandoz International GmbH
16.3.2. Celltrion, Inc.
16.3.3. Pfizer Inc.
16.3.4. Samsung Bioepis Co., Ltd.
16.3.5. Biocon Limited
16.3.6. Amgen Inc.
16.3.7. Fresenius Kabi AG
16.3.8. Boehringer Ingelheim International GmbH
16.3.9. Viatris Inc.
16.3.10. Dr. Reddy’s Laboratories Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BIOSIMILARS OF FACTOR X AGONISTS MARKET MULTI-CURRENCY
FIGURE 2. BIOSIMILARS OF FACTOR X AGONISTS MARKET MULTI-LANGUAGE
FIGURE 3. BIOSIMILARS OF FACTOR X AGONISTS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BIOSIMILARS OF FACTOR X AGONISTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BIOSIMILARS OF FACTOR X AGONISTS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOSIMILARS OF FACTOR X AGONISTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PLASMA-DERIVED FACTOR X, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RECOMBINANT FACTOR X, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY LIVER DISEASE RELATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY VITAMIN K ANTAGONIST-INDUCED, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY MODERATE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SEVERE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY LONG-TERM PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PERIOPERATIVE PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY POWDER FOR INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY READY-TO-USE INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRESCRIPTION SERVICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SUBSCRIPTION SERVICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY NURSE ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SELF-ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COMMUNITY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY TERTIARY CARE CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CARDIOLOGY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMOPHILIA TREATMENT CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 81. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 82. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 84. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 85. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 86. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 87. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 89. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 90. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 91. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 93. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 94. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 95. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 96. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 99. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 101. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 103. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 104. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 105. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 107. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 166. GERMANY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 167. GERMANY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. GERMANY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 169. GERMANY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 170. GERMANY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 171. GERMANY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 172. GERMANY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. GERMANY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 174. GERMANY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 175. GERMANY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 176. GERMANY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. GERMANY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 178. GERMANY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 179. GERMANY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 180. FRANCE BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 181. FRANCE BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. FRANCE BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 183. FRANCE BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 184. FRANCE BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 185. FRANCE BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 186. FRANCE BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. FRANCE BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 188. FRANCE BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 189. FRANCE BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 190. FRANCE BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. FRANCE BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 192. FRANCE BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 193. FRANCE BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 208. ITALY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 209. ITALY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. ITALY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 211. ITALY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 212. ITALY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 213. ITALY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 214. ITALY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. ITALY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 216. ITALY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 217. ITALY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 218. ITALY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. ITALY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 220. ITALY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 221. ITALY BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 222. SPAIN BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 223. SPAIN BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 224. SPAIN BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 225. SPAIN BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 226. SPAIN BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 227. SPAIN BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 228. SPAIN BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. SPAIN BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 230. SPAIN BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 231. SPAIN BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 232. SPAIN BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. SPAIN BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 234. SPAIN BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 235. SPAIN BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 252. SAUDI ARABIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 265. SOUTH AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 266. SOUTH AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 270. SOUTH AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 278. DENMARK BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 279. DENMARK BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 280. DENMARK BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2030 (USD MILLION)
TABLE 281. DENMARK BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 282. DENMARK BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 283. DENMARK BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 284. DENMARK BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. DENMARK BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 286. DENMARK BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 287. DENMARK BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 288. DENMARK BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. DENMARK BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 290. DENMARK BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Biosimilars of Factor X agonists market report include:
  • Sandoz International GmbH
  • Celltrion, Inc.
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Biocon Limited
  • Amgen Inc.
  • Fresenius Kabi AG
  • Boehringer Ingelheim International GmbH
  • Viatris Inc.
  • Dr. Reddy’s Laboratories Limited

Related Topics

Related Reports

Oral Biologics & Biosimilars Market Report 2025 - Product Image

Oral Biologics & Biosimilars Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Tocilizumab Biosimilars Market by Type, Dosage Forms, Application, Distribution Channel - Global Forecast to 2030 - Product Image

Tocilizumab Biosimilars Market by Type, Dosage Forms, Application, Distribution Channel - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From
Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 202 Pages
  • Global
From
2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA - Product Image

2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA

  • Report
  • 84 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.